open access

Ahead of print
Clinical vignette
Submitted: 2021-07-07
Accepted: 2021-07-16
Published online: 2021-10-06
Get Citation

Childhood thyroid carcinoma – an experience of one center

Hanna Borysewicz-Sańczyk1, Marta Pasławska2, Magdalena Zdrodowska2, Beata Sawicka1, Janusz Pomaski1, Daria Handkiewicz-Junak3, Jolanta Krajewska3, Agnieszka Czarniecka3, Barbara Jarzab3, Janusz Dzieciol4, Artur Bossowski1
DOI: 10.5603/EP.a2021.0086
·
Pubmed: 34647614
Affiliations
  1. Department of Pediatrics, Endocrinology, Diabetology with a Cardiology Division, Medical University of Bialystok, Poland
  2. Student Research Group by the Department of Pediatrics, Endocrinology, Diabetology with a Cardiology Division, Medical University of Bialystok, Waszyngtona 17, 15-274 Białystok, Poland
  3. Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology in Gliwice, Poland
  4. Department of Human Anatomy, Medical University of Bialystok, Poland

open access

Ahead of print
Clinical Vignette
Submitted: 2021-07-07
Accepted: 2021-07-16
Published online: 2021-10-06

Abstract

Papillary thyroid carcinoma (PTC) is the most common histological form of thyroid cancer in children and is characterized by a very good prognosis. However lymph node and lung metastases in PTC occur more frequently in pediatric patients than in adults. Ultrasound together with fine needle aspiration biopsy (FNAB) are the gold standard in the diagnosis of thyroid nodules in children. A new valuable diagnostic method became also elastography. The gold treatment standard remains thyroidectomy. In young patients with lymph node and/or distant metastases, there is abundant evidence to show that disease-free survival is improved by radioactive iodine (RAI) therapy. We present three patients diagnosed with PTC in Department of Paediatrics, Endocrinology, Diabetology with Cardiology Division, Medical University of Bialystok, Poland treated with the cooperation of the Department of Nuclear Medicine and Endocrine Oncology at M. Skłodowska-Curie National Research Institute in Gliwice, Poland.

Abstract

Papillary thyroid carcinoma (PTC) is the most common histological form of thyroid cancer in children and is characterized by a very good prognosis. However lymph node and lung metastases in PTC occur more frequently in pediatric patients than in adults. Ultrasound together with fine needle aspiration biopsy (FNAB) are the gold standard in the diagnosis of thyroid nodules in children. A new valuable diagnostic method became also elastography. The gold treatment standard remains thyroidectomy. In young patients with lymph node and/or distant metastases, there is abundant evidence to show that disease-free survival is improved by radioactive iodine (RAI) therapy. We present three patients diagnosed with PTC in Department of Paediatrics, Endocrinology, Diabetology with Cardiology Division, Medical University of Bialystok, Poland treated with the cooperation of the Department of Nuclear Medicine and Endocrine Oncology at M. Skłodowska-Curie National Research Institute in Gliwice, Poland.

Get Citation

Keywords

papillary thyroid carcinoma (PTC); children; thyroid ultrasonography; elastography; surgery, radioactive iodine (RAI)

About this article
Title

Childhood thyroid carcinoma – an experience of one center

Journal

Endokrynologia Polska

Issue

Ahead of print

Article type

Clinical vignette

Published online

2021-10-06

DOI

10.5603/EP.a2021.0086

Pubmed

34647614

Keywords

papillary thyroid carcinoma (PTC)
children
thyroid ultrasonography
elastography
surgery
radioactive iodine (RAI)

Authors

Hanna Borysewicz-Sańczyk
Marta Pasławska
Magdalena Zdrodowska
Beata Sawicka
Janusz Pomaski
Daria Handkiewicz-Junak
Jolanta Krajewska
Agnieszka Czarniecka
Barbara Jarzab
Janusz Dzieciol
Artur Bossowski

References (8)
  1. Niedziela M, Handkiewicz-Junak D, Małecka-Tendera E, et al. Diagnostics and treatment of differentiated thyroid carcinoma in children - Guidelines of Polish National Societies. Endokrynol Pol. 2016; 67(6): 628–642.
  2. Jarząb B, Dedecjus M, Słowińska-Klencka D, et al. Guidelines of Polish National Societies Diagnostics and Treatment of Thyroid Carcinoma. 2018 Update. Endokrynol Pol. 2018; 69(1): 34–74.
  3. Tessler FN, Middleton WD, Grant EG, et al. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee. J Am Coll Radiol. 2017; 14(5): 587–595.
  4. Perros P, Boelaert K, Colley S, et al. British Thyroid Association. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014; 81 Suppl 1: 1–122.
  5. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016; 26(1): 1–133.
  6. Czarniecka A, Woźniak G, Kropińska A, et al. Surgical approach to differentiated thyroid cancers (DTC) in children [Specyfika leczenia chirurgicznego zróżnicowanych raków tarczycy (ZRT) u dzieci]. Endokrynol Pol. 2019; 70(4): 357–366.
  7. Handkiewicz-Junak D, Wloch J, Roskosz J, et al. Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer. J Nucl Med. 2007; 48(6): 879–888.
  8. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003; 89(9): 1638–1644.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl